Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 1.65%
- Poor long term growth as Net Sales has grown by an annual rate of 1.18% and Operating profit at -188.91% over the last 5 years
- The company is Net-Debt Free
2
The company has declared Negative results for the last 7 consecutive quarters
3
Risky -
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,480 Million (Small Cap)
NA (Loss Making)
NA
0.13%
0.36
-10.97%
1.40
Revenue and Profits:
Net Sales:
328 Million
(Quarterly Results - Mar 2026)
Net Profit:
5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.13%
0%
5.13%
6 Months
2.23%
0%
2.23%
1 Year
-21.56%
0%
-21.56%
2 Years
-9.16%
0%
-9.16%
3 Years
-36.73%
0%
-36.73%
4 Years
-23.34%
0%
-23.34%
5 Years
-26.07%
0%
-26.07%
Shandong Sito Bio-technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.18%
EBIT Growth (5y)
-188.91%
EBIT to Interest (avg)
-0.06
Debt to EBITDA (avg)
5.40
Net Debt to Equity (avg)
0.35
Sales to Capital Employed (avg)
0.40
Tax Ratio
2.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.65%
ROE (avg)
1.52%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.61
EV to EBIT
-20.94
EV to EBITDA
1250.02
EV to Capital Employed
1.46
EV to Sales
3.85
PEG Ratio
NA
Dividend Yield
0.12%
ROCE (Latest)
-6.96%
ROE (Latest)
-9.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
328.00
259.90
26.20%
Operating Profit (PBDIT) excl Other Income
10.40
18.10
-42.54%
Interest
7.40
8.80
-15.91%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4.60
-32.00
114.38%
Operating Profit Margin (Excl OI)
31.80%
-89.20%
12.10%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 26.20% vs 6.34% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 114.38% vs -964.86% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
967.20
1,276.20
-24.21%
Operating Profit (PBDIT) excl Other Income
25.90
171.20
-84.87%
Interest
35.20
40.90
-13.94%
Exceptional Items
0.10
-0.20
150.00%
Consolidate Net Profit
-101.30
48.50
-308.87%
Operating Profit Margin (Excl OI)
-94.80%
48.40%
-14.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -24.21% vs -2.48% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -308.87% vs 14.12% in Dec 2023
About Shandong Sito Bio-technology Co., Ltd. 
Shandong Sito Bio-technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






